Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1015 participants
OBSERVATIONAL
2012-10-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation
NCT01140581
Dronedarone Rhythm Intervention for Early Atrial Fibrillation
NCT07270848
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial
NCT01288352
Driver-guided Ablation of Persistent Atrial Fibrillatiom
NCT04085731
A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.
NCT04045639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with dronedarone
Patients treated with dronedarone at inclusion
No interventions assigned to this group
Patients treated with other antiarrhythmic drugs of interest
The antiarrhythmic drugs of interest to which dronedarone will be compared are:
* Class 1a/1c antiarrhythmics
* Sotalol
* Amiodarone
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with paroxysmal or persistent atrial fibrillation
* Patient using an AAi (antiarrhythmic drug of interest) or dronedarone (index drug)
* Patient's treatment changed from one AAi to another AAi or dronedarone OR from no antiarrhythmic therapy to the start of AAi or dronedarone therapy during previous 6 months before the date of recruitment
* Patient with at least 6 months of medical and treatment information prior to the start of the index drug
* Patient able to answer the telephone interview in a language of the participating country: English, German, Italian or Spanish (with or without proxy).
Exclusion Criteria
* Patient with permanent Atrial Fibrillation
* Patient with psychiatric conditions preventing the participation to the study according to the physician
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
La-ser Europe Limited
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Artak Khachatryan, PhD
Role: STUDY_DIRECTOR
LA-SER Europe
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Praxis fuer Kardiologie, Im Muehlenbach 2B
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sanofi-EFFECT-AF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.